This page brings together the Agency's latest information on diabetes. It lists:
This is a summary of the European public assessment report (EPAR) for Jardiance. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use...
Xultophy is a medicine that is used for the treatment of type 2 diabetes. Together with diet and exercise, Xultophy is added to treatment with diabetes medicines taken by mouth when these medicines,...
This is a summary of the European public assessment report (EPAR) for Komboglyze. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use...
Eylea is a medicine used to treat adults with: the ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the...
This is a summary of the European public assessment report (EPAR) for Qtern. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is...
Fifteen new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting. The Committee recommended granting a marketing authorisation for Givlaari* (givosiran), the...
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorization in the European Union (EU) for Rybelsus (semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control...
EMA’s human medicines committee (CHMP) has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of children and adolescents aged 10 years or older with type 2 diabetes. This medicine is already approved...
EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of a tablet for certain patients with type 1 diabetes mellitus. Dapagliflozin is already authorised in the European Union as...
Diabetes patients reminded of importance of preventative foot care The European Medicines Agency (EMA) is informing about a potential increased risk of lower limb amputation (mostly affecting the toes) in patients taking the SGLT2 inhibitors...
Recommendations for patients with kidney impairment updated in product information The European Medicines Agency (EMA) has concluded that metformin-containing medicines can now be used in patients with moderately reduced kidney function (GFR [...